News/Blogs
New Generic Drug and Biosimilar Pipeline Report
We monitor the drug pipeline so you can ensure you provide your clients with the most clinically effective and cost-efficient options available. Here is what you can expect from our report:
- A list of newly approved brand-name drugs
- Key generic and biosimilar entries
- Administration routes, approval timelines, and cost projections
- Applicable therapeutic areas
We publish this pipeline report quarterly to assist your pharmacy benefit management planning and strategies. You can read about our clinical services and strategies or talk to a Sales Rep to learn more.
Download the Q2 2026 pipeline report PDF to save and share it with your clients and colleagues.
New Drug Pipeline
| GENERIC NAME | BRAND NAME (Manufacturer if drug name unavailable) | ROUTE OF ADMINISTRATION | STATUS | ESTIMATED COST | THERAPEUTIC AREA | SPECIALTY OR TRADITIONAL |
|---|---|---|---|---|---|---|
| icotrokinra | (Johnson & Johnson) | Oral | March 2026 | $50,000 -$100,000 | Dermatology | Specialty |
| orforglipron Calcium | (Eli Lilly) | Oral | April 2026 | $10,000 – $18,000 annually | Sleep Apnea / Weight Management | Traditional |
| baxdrostat | (AstraZeneca) | Oral | Q2 2026 | $5,000 – $10,000 annually | Cardiology | Traditional |
| cytisinicline | (Achieve Life Sciences) | Oral | June 2026 | $1,000 | Behavior Health | Traditional |
| TRN-257 | (Tris Pharma) | Oral | June 2026 | $100,000 -$200,000 annually | Sleep | Specialty |
| tavapadon | (Pfizer / AbbVie) | Oral | Q3 2026 | $10,000 – $20,000 annually | Parkinson’s Disease | Traditional |
| imsidolimab | (AnaptysBio; Vanda Pharmaceuticals) | Intravenous; Subcutaneous | 2026 | $200,000- $300,000 annually | Dermatology | Specialty |
| tebipenem | (GSK, Spero Therapeutics) | Oral | 2026 | $5,000 – $10,000 per treatment course | Infectious disease | Traditional |
| insulin efsitora alfa | (Eli Lilly) | Subcutaneous | 2026 | $5,000 | Endocrinology | Traditional |
Generic Pipeline
| DRUG NAME | BRAND NAME | ROUTE OF ADMINISTRATION | STATUS / EST LOE PROB | ESTIMATED 2024 US SALES (MILLIONS) | THERAPEUTIC AREA | BIOSIMILAR OR TRADITIONAL |
|---|---|---|---|---|---|---|
| metformin; sitagliptin | Janumet | Oral | May 2026 | 1,354 | Endocrine: Diabetes | Traditional |
| sitagliptin | Januvia | Oral | May 2026 | 6,397 | Endocrine: Diabetes | Traditional |
| brivaracetam | Briviact | Oral | 2026 | 818 | Epilepsy | Traditional |
Biosimilar Pipeline
| GENERIC NAME | BRAND NAME (Manufacturer if drug name unavailable) | ROUTE OF ADMINISTRATION | STATUS | ESTIMATED COST | THERAPEUTIC AREA | BIOSIMIALR OR TRADITIONAL |
|---|---|---|---|---|---|---|
| nintedanib | Ofev | Oral | April 2026 | 2,979 | Pulmonology | Biosimilar |
| Insulin glargine | Lantus | Subcutaneous | May 2026 | 1,800 | Endocrine: Diabetes | Traditional |
| tofacitinib Citrate | Xeljanz | Oral | Q2 2026 | 4,304 | Autoimmune | Biosimilar |
| Insulin aspart | Novolog | Subcutaneous | July 2026 | 1,200 | Endocrine: Diabetes | Traditional |
| Insulin lispro | Humalog | Subcutaneous | 2026 | 1,800 | Endocrine: Diabetes | Traditional |
| golimumab | Simponi | Subcutaneous | 2026 | 3,700 | Autoimmune | Biosimilar |
| abatacept | Orencia | Subcutaneous | 2026 | 4,900 | Autoimmune | Biosimilar |
| omalizumab | Xolair | Subcutaneous | 2026 | 3,900 | Autoimmune | Biosimilar |
Nothing herein is or shall be construed as a promise or representation regarding past or future events, and Serve You Rx expressly disclaims any and all liability relating to the use or reliance on the information contained in this publication. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to, or disclosed to others at any time without the prior written consent of Serve You Rx.
KEY
| Date | Updated release date |
| MONTH YYYY | Launch Date |
Past Quarterly Pipeline Reports
Click the links below to download past quarterly reports.
About Serve You Rx®
Serve You Rx is a full-service pharmacy benefit manager (PBM) with unquestionable flexibility and an unwavering commitment to doing what’s best for its clients. With a fervent focus on those it serves, including insurance brokers, consultants, third-party administrators, and their clients, Serve You Rx delivers exceptional service and tailored, cost-effective benefit solutions. Independent and privately held for nearly 40 years, Serve You Rx can implement new groups in 30 days or less and say “yes” to a wide variety of viable solutions. Known for its adaptability, quality, and client-centricity, Serve You Rx aims to be a benchmark for better client service.
